Work

Abstract A174: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and cetuximab.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-a174

Authors: Neil Senzer, Daniel Bowles, Roger B. Cohen, Alex Vo, Kevin Klucher, Scott Peterson, Diana F. Hausman, Antonio Jimeno

Institutions: Mary Crowley Cancer Research Center, University of Colorado Cancer Center, Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4249350366

Cites:

Cited by: 1

Related to: 10